Perception Neuroscience

Focus: Perception Neuroscience is a biotechnology company focused on ketamine derivative therapeutics for neurology and psychiatry indications. Company stage, size, and financial position are undisclosed.

Neurology Psychiatry

Profile data last refreshed 20h ago · AI intelligence enriched 1w ago

Open Jobs

About Perception Neuroscience

AI assessmentNot Hiring

No open roles listed right now. Follow Perception Neuroscience to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resi

Treatment-Resistant Depression

N/A

Clinical Trials (1)

NCT06232291Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression

N/A

Help build intelligence for Perception Neuroscience

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline in high-need therapeutic areas (neurology and psychiatry) with significant unmet medical need
Opportunity to work on novel ketamine-derivative mechanism in a specialized biotech setting
New York headquarters location provides access to major pharma, biotech, and funding networks

Watch Out For

Zero active clinical trials reported, suggesting very early stage or undisclosed pipeline status
No current job openings and minimal disclosed employee count raises questions about company scale and growth trajectory
Limited public visibility: no funding data, publications, financial disclosures, or recent news available for evaluation

Generated by Claude from Perception Neuroscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

PCN-101

Treatment Resistant Depression

Phase 2

Clinical Trials (1)

NCT05414422A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

2 pipeline

Marketed

Pipeline